Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Teva Targets Big Cuts In Staffing
by Ann M. Thayer
October 14, 2013
| A version of this story appeared in
Volume 91, Issue 41
Teva Pharmaceutical Industries is accelerating a cost-cutting program put in place last December. By the end of 2014, the Israeli company will reduce its workforce by about 10%, or 5,000 employees. Through job cuts, asset sales, and improved manufacturing efficiency, it is targeting $2.0 billion in annual savings by the end of 2017. Known primarily as a generic drug firm, Teva has been building its R&D programs and will put some of the savings into programs for complex generics and specialty medicines. The announcement comes soon after Merck & Co. said it would cut 16,000 jobs, nearly 20% of its workforce.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X